Research programme: neurological disorders therapies - Vyrex/Immune Response

Drug Profile

Research programme: neurological disorders therapies - Vyrex/Immune Response

Latest Information Update: 03 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Response Corporation; Vyrex Corporation
  • Class
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS trauma; Spinal cord injuries

Most Recent Events

  • 01 Aug 2003 Discontinued - Preclinical for CNS trauma in USA (unspecified route)
  • 01 Aug 2003 Discontinued - Preclinical for Spinal cord injuries in USA (unspecified route)
  • 30 Jun 1998 Preclinical trials in CNS trauma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top